Insights into Renal Cell Carcinoma (RCC) 2020
Current treatment practice regarding therapy of advanced renal cell carcinoma (RCC), recently introduced and upcoming agents
Southern California and Arizona – December 3, 2020
Faculty Chair
Sumanta Kumar Pal, MD
City of Hope Comprehensive Cancer Center, Duarte, CA
REPORT SNAPSHOT
- A roundtable discussion, moderated by an Axess Oncology Network physician, focusing on treatment of advanced RCC was held on December 3, 2020, in a virtual setting
- Disease state and data presentations were developed by Sumanta Kumar Pal, MD, a medical expert from City of Hope Comprehensive Cancer Center, Duarte, California
- The group of advisors comprised 12 community oncologists from practices in the southwest United States
- Insights on the following therapies were obtained: sunitinib, pazopanib, cabozantinib, axitinib, lenvatinib, ipilimumab, pembrolizumab, nivolumab, avelumab, everolimus, and combinations of these drugs
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection was accomplished through use of audience response system (ARS) questioning and moderated discussion
- Attendees of the roundtable represented community oncologists from practices across Southern California and Arizona
